ARCTArcturus Therapeutics Holdings
−7.6% today · −47.7% over a year
1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 4% of the instruments we score
Quality, Stability: among the weakest; priced higher than most peers. No dividend.
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 212)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Volatility (1 y)weighs on the score · better than 5% of peers
- 12-month trend (ex last month)weighs on the score · better than 13% of peers
- Piotroski F-scoreweighs on the score · better than 3% of peers
Red flags and notes
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/B
- 1.8
- P/S
- 10.8
- Market cap (EUR)
- €282M
Profitability and debt
- Return on equity
- −46.3%
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- −7.6%
- 1 month
- −27.3%
- 1 year
- −47.7%
- Volatility, 1 yr
- 102.2%
- Max drawdown, 1 yr
- −76.1%
- Beta
- 1.82
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
News and filings
- Arcturus Therapeutics Holdings Inc.: 8-K — Regulation FD disclosure
FactSEC EDGAR · Filing · 24 9月 2026
- Arcturus Therapeutics Holdings Inc.: 8-K — Regulation FD disclosure
FactSEC EDGAR · Filing · 25 8月 2026
- Arcturus Therapeutics Holdings Inc.: 10-Q — Quarterly report for the period ending 2026-06-30
FactSEC EDGAR · Filing · 7 8月 2026
- Arcturus Therapeutics Holdings Inc.: 8-K — Results of operations
FactSEC EDGAR · Filing · 7 8月 2026
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | 1/10 | 1 · — | Caution. Negative free cash flow in at least two of the last three years. More in the glossary → | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.